{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T01:54:28Z","timestamp":1782784468509,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To analyze the risk factors influencing the development of cefoperazone-induced coagulopathy in critically ill patients and determine the threshold of serum trough concentration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective case-control study was conducted in the intensive care unit patients treated with cefoperazone, and it was approved by the Ethical Committee of Drum Tower Hospital affiliated with the Medical School of Nanjing University (NO.2023-158-01). Patients were divided into the normal group and coagulopathy group based on prothrombin time. The clinical characteristics of the two groups were compared using univariate analysis. The serum concentration threshold and influencing factors of cefoperazone-induced coagulopathy in critically ill patients were analyzed using the receiver operating characteristic curve and multivariate logistic regression analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 113 patients were included, and cefoperazone-induced coagulopathy occurred in 39 patients, with an incidence of 34.5%. These patients experienced significant prothrombin time prolongation around day 6 (median) after cefoperazone application. The serum trough concentration threshold of cefoperazone-induced coagulopathy in critically ill patients was 87.765\u00a0mg\/l. Multivariate logistic regression analysis revealed that the APACHE II score (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.034), prophylactic use of vitamin K\n                      <jats:sub>1<\/jats:sub>\n                      (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), hepatic impairment (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.014), and C\n                      <jats:sub>min<\/jats:sub>\n                      \u2009\u2265\u200987.765\u00a0mg\/l (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005) were associated with cefoperazone-induced coagulopathy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Cefoperazone-induced coagulopathy usually occurs on the 6th day of cefoperazone use in critically ill patients. The risk will increase in patients with an APACHE II score\u2009&gt;\u200925, hepatic impairment, and cefoperazone C\n                      <jats:sub>min<\/jats:sub>\n                      \u2009\u2265\u200987.765\u00a0mg\/l. Vitamin K\n                      <jats:sub>1<\/jats:sub>\n                      is effective in preventing this adverse reaction.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00228-024-03634-4","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T10:03:02Z","timestamp":1707904982000},"page":"737-746","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Serum trough concentration threshold and risk factors of cefoperazone-induced coagulopathy in critically ill patients: A retrospective case-control study"],"prefix":"10.1007","volume":"80","author":[{"given":"Qian","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binbin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,14]]},"reference":[{"key":"3634_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.13461\/j.cnki.cja.007271","volume":"01","author":"R Chen","year":"2022","unstructured":"Chen R, Ma D, Cai X et al (2022) Quality assessment of domestic cefoperazone sodium and sulbactam sodium for injection. Chinese J Antibiotics 01:55\u201365. https:\/\/doi.org\/10.13461\/j.cnki.cja.007271","journal-title":"Chinese J Antibiotics"},{"key":"3634_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.15912\/j.cnki.gocm.2020.29.043","volume":"29","author":"Q Dai","year":"2020","unstructured":"Dai Q, Lv B (2020) Clinical effect of cefoperazone combined with sulbactam in the treatment of patients with pyelonephritis and its influence on liver and kidney function. Guide China Med 29:91\u201392. https:\/\/doi.org\/10.15912\/j.cnki.gocm.2020.29.043","journal-title":"Guide China Med"},{"key":"3634_CR3","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3760\/cma.j.cn112137-20200202-00178","volume":"100","author":"XX Du","year":"2020","unstructured":"Du XX, Lv XJ, Qu JY et al (2020) Experts consensus of clinical application of \u03b2-lactam antibiotics\/\u03b2-lactamase inhibitor combination preparations (2020 edition). Natl Med J China 100:738\u2013747. https:\/\/doi.org\/10.3760\/cma.j.cn112137-20200202-00178","journal-title":"Natl Med J China"},{"key":"3634_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s40800-016-0025-9","volume":"1","author":"Z Cai","year":"2016","unstructured":"Cai Z, Yang W, He Y et al (2016) Cefoperazone\/sulbactam-induced abdominal wall hematoma and upper gastrointestinal bleeding: a case report and review of the literature. Drug Saf Case Rep 1:2. https:\/\/doi.org\/10.1007\/s40800-016-0025-9","journal-title":"Drug Saf Case Rep"},{"key":"3634_CR5","doi-asserted-by":"publisher","first-page":"OD10","DOI":"10.7860\/JCDR\/2016\/19694.8316","volume":"8","author":"GR Katukuri","year":"2016","unstructured":"Katukuri GR, Maddala RN, Ramamoorthi K et al (2016) cefoperazone induced gastrointestinal bleeding. J Clinical Diagnostic Res 8:OD10\u2013OD11. https:\/\/doi.org\/10.7860\/JCDR\/2016\/19694.8316","journal-title":"J Clinical Diagnostic Res"},{"key":"3634_CR6","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M et al (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (London, England) 370:1453\u20131457. https:\/\/doi.org\/10.1016\/S0140-6736(07)61602-X","journal-title":"Lancet (London, England)"},{"key":"3634_CR7","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2165\/00044011-200626080-00006","volume":"8","author":"H Alagozlu","year":"2006","unstructured":"Alagozlu H, Cindoruk M, Unal S (2006) Severe INR elevation in a patient with choledocholithiasis receiving cefoperazone. Clin Drug Investig 8:481\u2013484. https:\/\/doi.org\/10.2165\/00044011-200626080-00006","journal-title":"Clin Drug Investig"},{"key":"3634_CR8","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.3969\/j.issn.1672-9455.2020.16.022","volume":"16","author":"Y Ling","year":"2020","unstructured":"Ling Y, Tan M (2020) Effects of vitamin K1 injection on coagulation function in bacterial infected patients with cefoperazone sulbactam in ICU. Lab Med Clin 16:2347\u20132349. https:\/\/doi.org\/10.3969\/j.issn.1672-9455.2020.16.022","journal-title":"Lab Med Clin"},{"key":"3634_CR9","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.3390\/ijerph16203937","volume":"20","author":"GH Park","year":"2019","unstructured":"Park GH, Kim S, Kim MS et al (2019) The association between cephalosporin and hypoprothrombinemia: a systematic review and meta-analysis. Int J Environ Res Public Health 20:3937. https:\/\/doi.org\/10.3390\/ijerph16203937","journal-title":"Int J Environ Res Public Health"},{"key":"3634_CR10","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/j.1875-9114.1989.tb04122.x","volume":"3","author":"TH Grasela","year":"1989","unstructured":"Grasela TH, Walawander CA, Welage LS et al (1989) Prospective surveillance of antibiotic-associated coagulopathy in 970 patients. Pharmacotherapy 3:158\u2013164. https:\/\/doi.org\/10.1002\/j.1875-9114.1989.tb04122.x","journal-title":"Pharmacotherapy"},{"key":"3634_CR11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/TA.0000000000001282","volume":"2","author":"B Shenkman","year":"2017","unstructured":"Shenkman B, Budnik I, Einav Y et al (2017) Model of trauma-induced coagulopathy including hemodilution, fibrinolysis, acidosis, and hypothermia: impact on blood coagulation and platelet function. J Trauma Acute Care Surg 2:287\u2013292. https:\/\/doi.org\/10.1097\/TA.0000000000001282","journal-title":"J Trauma Acute Care Surg"},{"key":"3634_CR12","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00228-016-2045-x","volume":"7","author":"C Gao","year":"2016","unstructured":"Gao C, Tong J, Yu K et al (2016) Pharmacokinetics of cefoperazone\/sulbactam in critically ill patients receiving continuous venovenous hemofiltration. Eur J Clin Pharmacol 7:823\u2013830. https:\/\/doi.org\/10.1007\/s00228-016-2045-x","journal-title":"Eur J Clin Pharmacol"},{"key":"3634_CR13","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/MCC.0000000000000466","volume":"6","author":"J Stensballe","year":"2017","unstructured":"Stensballe J, Henriksen HH, Johansson PI (2017) Early haemorrhage control and management of trauma-induced coagulopathy: the importance of goal-directed therapy. Curr Opin Crit Care 6:503\u2013510. https:\/\/doi.org\/10.1097\/MCC.0000000000000466","journal-title":"Curr Opin Crit Care"},{"key":"3634_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158407","volume":"7","author":"LJ Chen","year":"2016","unstructured":"Chen LJ, Hsiao FY, Shen LJ et al (2016) Use of hypoprothrombinemia-inducing cephalosporins and the risk of hemorrhagic events: a nationwide nested case-control study. PLoS ONE 7:e0158407. https:\/\/doi.org\/10.1371\/journal.pone.0158407","journal-title":"PLoS ONE"},{"key":"3634_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/(SICI)1099-1557(199903\/04)8:2<81::AID-PDS411>3.0.CO;2-G","volume":"2","author":"BL Strom","year":"1999","unstructured":"Strom BL, Schinnar R, Gibson GA et al (1999) Risk of bleeding and hypoprothrombinaemia associated with NMTT side chain antibiotics: using cefoperazone as a test case. Pharmacoepidemiol Drug Saf 2:81\u201394. https:\/\/doi.org\/10.1002\/(SICI)1099-1557(199903\/04)8:2%3c81::AID-PDS411%3e3.0.CO;2-G","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3634_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/BF01644806","volume":"1","author":"K Andrassy","year":"1986","unstructured":"Andrassy K, Koderisch J, Fritz S et al (1986) Alteration of hemostasis associated with cefoperazone treatment. Infection 1:27\u201331. https:\/\/doi.org\/10.1007\/BF01644806","journal-title":"Infection"},{"key":"3634_CR17","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3969\/j.issn.1001-9057.2003.09.003","volume":"09","author":"Y Chen","year":"2003","unstructured":"Chen Y, Shen Z (2003) Haematological adverse effects of cephalosporin. J Clin Intern Med 09:455\u2013457. https:\/\/doi.org\/10.3969\/j.issn.1001-9057.2003.09.003","journal-title":"J Clin Intern Med"},{"key":"3634_CR18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/j.1552-4604.1988.tb03106.x","volume":"1","author":"MJ Shearer","year":"1988","unstructured":"Shearer MJ, Bechtold H, Andrassy K et al (1988) Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status. J Clin Pharmacol 1:88\u201395. https:\/\/doi.org\/10.1002\/j.1552-4604.1988.tb03106.x","journal-title":"J Clin Pharmacol"},{"key":"3634_CR19","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1128\/AAC.29.6.1108","volume":"6","author":"G Agnelli","year":"1986","unstructured":"Agnelli G, Del Favero A, Parise P et al (1986) Cephalosporin-induced hypoprothrombinemia: is the N-methylthiotetrazole side chain the culprit? Antimicrob Agents Chemother 6:1108\u20131109. https:\/\/doi.org\/10.1128\/AAC.29.6.1108","journal-title":"Antimicrob Agents Chemother"},{"key":"3634_CR20","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/BF01704604","volume":"3","author":"SD Rockoff","year":"1992","unstructured":"Rockoff SD, Blumenfrucht MJ, Irwin RJ et al (1992) Vitamin K supplementation during prophylactic use of cefoperazone in urologic surgery. Infection 3:146\u2013148. https:\/\/doi.org\/10.1007\/BF01704604","journal-title":"Infection"},{"key":"3634_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1476-0711-12-38","volume":"12","author":"X Xin","year":"2013","unstructured":"Xin X, Jian L, Xia X et al (2013) A multicentre clinical study on the injection of ceftriaxone\/sulbactam compared with cefoperazone\/sulbactam in the treatment of respiratory and urinary tract infections. Ann Clin Microbiol Antimicrob 12:38. https:\/\/doi.org\/10.1186\/1476-0711-12-38","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"1","key":"3634_CR22","doi-asserted-by":"publisher","first-page":"741","DOI":"10.11669\/cpj.2022.09.009","volume":"9","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Liang L, Shen J et al (2022) Clinical features and risk factors of coagulation disorders caused by cefoperazone sodium and sulbactam sodium. Chin Pharm J 9(1):741\u2013746. https:\/\/doi.org\/10.11669\/cpj.2022.09.009","journal-title":"Chin Pharm J"},{"key":"3634_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/0002-9343(86)90256-1","volume":"2","author":"FR Sattler","year":"1986","unstructured":"Sattler FR, Colao DJ, Caputo GM et al (1986) Cefoperazone for empiric therapy in patients with impaired renal function. Am J Med 2:229\u2013236. https:\/\/doi.org\/10.1016\/0002-9343(86)90256-1","journal-title":"Am J Med"},{"key":"3634_CR24","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","volume":"10","author":"WA Knaus","year":"1985","unstructured":"Knaus WA, Draper EA, Wagner DP et al (1985) APACHE II: a severity of disease classification system. Crit Care Med 10:818\u2013829","journal-title":"Crit Care Med"},{"key":"3634_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/s0261-5614(02)00214-5","volume":"3","author":"J Kondrup","year":"2003","unstructured":"Kondrup J, Rasmussen HH, Hamberg O et al (2003) Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin Nut (Edinburgh, Scotland) 3:321\u2013336. https:\/\/doi.org\/10.1016\/s0261-5614(02)00214-5","journal-title":"Clin Nut (Edinburgh, Scotland)"},{"key":"3634_CR26","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s12098-014-1584-3","volume":"82","author":"F Aziz","year":"2015","unstructured":"Aziz F, Patil P (2015) Role of prophylactic vitamin K in preventing antibiotic induced hypoprothrombinemia. Indian J Pediatr 82:363\u2013367. https:\/\/doi.org\/10.1007\/s12098-014-1584-3","journal-title":"Indian J Pediatr"},{"key":"3634_CR27","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1080\/14740338.2020.1713090","volume":"3","author":"W Wang","year":"2020","unstructured":"Wang W, Liu Y, Yu C et al (2020) Cefoperazone-sulbactam and risk of coagulation disorders or bleeding: a retrospective cohort study. Expert Opin Drug Saf 3:339\u2013347. https:\/\/doi.org\/10.1080\/14740338.2020.1713090","journal-title":"Expert Opin Drug Saf"},{"key":"3634_CR28","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1128\/AAC.04305-14","volume":"3","author":"Q Zhang","year":"2015","unstructured":"Zhang Q, Zhou S, Zhou J (2015) Tigecycline treatment causes a decrease in fibrinogen levels. Antimicrob Agents Chemother 3:1650\u20131655. https:\/\/doi.org\/10.1128\/AAC.04305-14","journal-title":"Antimicrob Agents Chemother"},{"key":"3634_CR29","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00228-020-02860-w","volume":"7","author":"J Hu","year":"2020","unstructured":"Hu J, Xiao YH, Zheng Y et al (2020) Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients. Eur J Clin Pharmacol 7:913\u2013922. https:\/\/doi.org\/10.1007\/s00228-020-02860-w","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"3634_CR30","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1248\/cpb.c18-00844","volume":"67","author":"B Leng","year":"2019","unstructured":"Leng B, Xue YC, Zhang W et al (2019) A retrospective analysis of the effect of tigecycline on coagulation function. Chem Pharm Bull 67(3):258\u2013264. https:\/\/doi.org\/10.1248\/cpb.c18-00844","journal-title":"Chem Pharm Bull"},{"key":"3634_CR31","doi-asserted-by":"publisher","first-page":"6277","DOI":"10.2147\/IDR.S429706","volume":"16","author":"W Miao","year":"2023","unstructured":"Miao W, Guo J, Cheng H et al (2023) Risk factors for cefoperazone\/sulbactam-induced coagulation disorder. Infect Drug Resist 16:6277\u20136284. https:\/\/doi.org\/10.2147\/IDR.S429706","journal-title":"Infect Drug Resist"},{"key":"3634_CR32","doi-asserted-by":"publisher","first-page":"1182644","DOI":"10.3389\/fphar.2023.1182644","volume":"14","author":"L Zhang","year":"2023","unstructured":"Zhang L, Cai X, Peng F et al (2023) Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone\/sulbactam therapy and other tigecycline-based combination therapies. Front Pharmacol 14:1182644. https:\/\/doi.org\/10.3389\/fphar.2023.1182644","journal-title":"Front Pharmacol"},{"key":"3634_CR33","doi-asserted-by":"publisher","first-page":"e335","DOI":"10.1016\/j.clinthera.2021.10.005","volume":"43","author":"SX Wu","year":"2021","unstructured":"Wu SX, Wu G, Wu HB (2021) A comparison of coagulation function inpatients receiving aspirin and cefoperazone-sulbactam with and without vitamin K1: a retrospective, observational study. Clin Ther 43:e335\u2013e345. https:\/\/doi.org\/10.1016\/j.clinthera.2021.10.005","journal-title":"Clin Ther"},{"key":"3634_CR34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.5005\/jp-journals-10071-24417","volume":"27","author":"KK Gudivada","year":"2023","unstructured":"Gudivada KK, Krishna B, Sampath S (2023) Cefoperazone-induced coagulopathy in critically ill patients admitted to intensive care unit. Indian journal of critical care medicine 27:183\u2013189. https:\/\/doi.org\/10.5005\/jp-journals-10071-24417","journal-title":"Indian journal of critical care medicine"},{"key":"3634_CR35","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/j.1875-9114.1987.tb03522.x","volume":"3","author":"JJ Schentag","year":"1987","unstructured":"Schentag JJ, Welage LS, Grasela TH et al (1987) Determinants of antibiotic-associated hypoprothrombinemia. Pharmacotherapy 3:80\u201386. https:\/\/doi.org\/10.1002\/j.1875-9114.1987.tb03522.x","journal-title":"Pharmacotherapy"},{"key":"3634_CR36","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1124\/dmd.107.019125","volume":"36","author":"Y Kato","year":"2008","unstructured":"Kato Y, Takahara S, Kato S et al (2008) Involvement of multidrug resistance-associated protein 2 (Abcc2) in molecular weight-dependent biliary excretion of beta-lactam antibiotics. Drug Metab Dispos 36:1088\u20131096. https:\/\/doi.org\/10.1124\/dmd.107.019125","journal-title":"Drug Metab Dispos"},{"key":"3634_CR37","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/978-3-642-14541-4_8","volume":"201","author":"D Keppler","year":"2011","unstructured":"Keppler D (2011) Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy. Handb Exp Pharmacol 201:299\u2013323. https:\/\/doi.org\/10.1007\/978-3-642-14541-4_8","journal-title":"Handb Exp Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03634-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03634-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03634-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T02:09:44Z","timestamp":1712542184000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03634-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,14]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["3634"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03634-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3085607\/v1","asserted-by":"object"}]},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,14]]},"assertion":[{"value":"20 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethical Committee of Drum Tower Hospital affiliated with the Medical School of Nanjing University (NO.2023-158-01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}